Purpose: Physical activity conveys health benefits for people with osteoarthritis (OA). Epidemiological studies often use self-reported instruments to explore this relationship, but these measures do not effectively capture actual time spent in physical activity in varying intensities. Public health physical activity guidelines are tied to time spent in physical activity of moderate/vigorous intensity. This study utilizes accelerometers to objectively assess time spent in moderate/vigorous physical activity (MVPA) in adults with knee OA. We investigated the correlation of objective measures with less burdensome subjective measures from Physical Activity Scale in the Elderly (PASE) scores. We also evaluated the association of subjective and objective measures to physical function. Methods: Cross-sectional accelerometer data from 969 adults aged 55 and above with radiographic knee OA (Kellgren-Lawrence 2 in one or both knees) participating in the Osteoarthritis Initiative accelerometer monitoring ancillary study was assessed for physical activity and function. Participants' response to the PASE questionnaire was followed by 7 days of accelerometer monitoring. Accelerometer measures included average daily minutes in MVPA and average daily minutes in MVPA sessions of 10 minutes or more (MVPA bouts). Other subjective measures including WOMAC (Western Ontario MacMaster) function, SF12 (12-Item Short Form Health Survey) physical function, objective measure gait speed averaged from two 20 meter walks, and covariables including demographics (age, gender), and heath factors (BMI and waist circumference) were assessed. Results: Mean PASE score was 149.80 (SD¼78.4) and mean accelerometer MVPA was 15.55 minutes/day (SD¼17.18). PASE scores were modestly correlated with average daily minutes in MVPA (r¼0.31) and MVPA bouts (r¼0.21). PASE scores correlated better with accelerometer measures of MVPA and MVPA bouts in participants who were particularly inactive (characterized by older age, higher BMI, and greater waist circumference). There were no significant gender effects. Accelerometer measures of MVPA and MVPA bouts compared to PASE scores had stronger correlation in WOMAC function (r:-0.14, -0.12 versus -0.02), SF12 physical function (r: 0.22, 0.19, versus 0.07), and gait speed (r: 0.35, 0.29, versus 0.16). Conclusions: In this population with radiographic knee OA, modest correlations of PASE with accelerometer MVPA assessments limit the ability to use this self-reported instrument to explore relationships of activity intensity and OA. Accelerometry data are complementary and help to better characterize the effects of physical activity on health outcomes. Accelerometer MVPA and MVPA bouts were more strongly associated with physical function than PASE, although that correlation was modest at best. The choice of PASE versus objective measurement for future epidemiologic studies must take into account the purpose for which physical activity is being measured. Purpose: In France, the cost of an osteoarthritic patient has not been estimated for several years. The aim of the study was to evaluate the annual cost of the treatment given to osteoarthritic patients by GP. Methods: The cohort was made up of patients who were diagnosed with osteoarthritis between April 2009 and March 2010 (IMS Disease Analyzer database) The cost includes all medical cost to the patients in the cohort, and colligated in the Disease Analyzer database (all consultations with GPs and all resulting drug prescriptions). The evaluated cost is therefore the annual cost of treatment given to an osteoarthritic patient.
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Results: 18 976 patients suffering from osteoarthritis were followed. For these patients, who had an average age of 66, all consultations with GPs as well as all resulting drug prescriptions were valued both in terms of societal cost and cost to health insurance. The average annual cost of disease management by a GP of a patient suffering from osteoarthritis is therefore valued at V755 societal cost, of which around 60% (V447) is paid by health insurance. The annual cost of treatment by a GP of a patient suffering from hip osteoarthritis is significantly lower at the societal level (V715) than at the health insurance level (V425) compared to patients suffering from osteoarthritis in the knee or elsewhere, despite their higher age.
Conclusions:
No literary data evaluating the cost of an osteoarthritic patient currently exists. The closest data is that produced by a COARTÒ France study (Le Pen and coll, Revue du rhumatisme, December 2005). The prevalence of osteoarthritis has been estimated at around 4 million sufferers, even though this figure may be conservative, we can estimate that the cost of osteoarthritis treatment is around 3 billion euros. We are sure that further data will be added to existing ones. We excluded periprosthetic fractures occurring in the knee or shoulder region. We used the incidence density method to calculate the annual incidence of each fracture. Time 'at risk' was defined from the beginning of observation (January 2006) to one of the three events, whichever occurred first: 1) death, 2) fracture or 3) end of the observation period (December 2008). We used multivariate Cox proportional hazards models to identify risk factors for periprosthetic fractures and for non-implant related femoral fractures, including sex, age, race, number of non-elective hospitalizations in the prior decade (a proxy for comorbidity), eligibility for Medicaid (a proxy for low income) and number
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